CONSOLIDATED AND COMBINED STATEMENTS OF EQUITY CONSOLIDATED AND COMBINED STATEMENTS OF EQUITY (USD $) In Millions, unless otherwise specified		Total		Business Unit Equity		Common Stock		Additional Paid-in Capital	Retained Earnings	Accumulated Other Comp. Income/(Loss)	Equity Attributable to Noncontrolling Interests
Beginning balance at Dec. 31, 2010		$ 3,344		$ 3,418	[1]			$ 0	$ 0	$ (74)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Comprehensive income		257	[2]	245	[1]					9	3
Share-based compensation expense		19		19	[1]
Investment in Jilin Pfizer Guoyuan Animal Health Co., Ltd.		16									16
Dividends declared and paid		(416)		(416)	[1]
Net transfers between Pfizer and noncontrolling interests		0		3	[1]						(3)
Net transfers - Pfizer	[1]	516		516
Ending balance at Dec. 31, 2011		3,736		3,785	[1]				0	(65)	16
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Comprehensive income		344		436	[1]					(92)
Share-based compensation expense		28		28	[1]
Dividends declared and paid		(63)		(63)	[1]
Net transfers between Pfizer and noncontrolling interests		0		1	[1]						(1)
Net transfers - Pfizer		(4)		(4)	[1]
Ending balance at Dec. 31, 2012		4,041	[3]	4,183					0	(157)	15
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Comprehensive income		447		94	[1]				410	(56)	(1)
Share-based compensation expense		43		3	[1]			40
Dividends declared and paid		(134)							(134)
Net transfers - Pfizer		(271)		(271)	[1]
Separation adjustments(c)	[4]	445		414	[1]			29		(6)	8
Employee benefit plan contribution from Pfizer Inc.(d)	[5]	2						2
Reclassification of net liability due to Pfizer Inc.(e)	[6]	(60)		(60)	[1]
Consideration paid to Pfizer Inc. in connection with the Separation(f)	[7]	(3,551)						(3,551)
Issuance of common stock to Pfizer Inc. in connection with the Separation and relassification of Business Unit Equity(f)	[7]	0		(4,363)	[1]	5	[8]	4,358
Ending balance at Dec. 31, 2013		$ 962	[3]			$ 5	[8]	$ 878	$ 276	$ (219)	$ 22

[1] All amounts associated with Business Unit Equity relate to periods prior to the Separation. See Note 2A. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer— The Separation.

[2] Includes impacts from acquisitions from the acquisition date, see Note 3. Basis of Presentation and Note 5. Acquisitions, Divestitures and Certain Investments.

[3] The consolidated balance sheet as of December 31, 2013 has been prepared under a different basis of presentation than the combined balance sheet as of December 31, 2012, which significantly impacts comparability. See Note 3. Basis of Presentation.

[4] For additional information, see Note 2B. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer—Adjustments Associated with the Separation.

[5] Represents contributed capital from Pfizer Inc. associated with service credit continuation for certain Zoetis Inc. employees in Pfizer Inc.'s U.S. qualified defined benefit and U.S. retiree medical plans. See Note 14. Benefit Plans.

[6] Represents the reclassification of the Receivable from Pfizer Inc. and the Payable to Pfizer Inc. from Business Unit Equity as of the Separation date. See Note 2A. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer— The Separation.

[7] Reflects the Separation transaction. See Note 2A. The Separation, Adjustments Associated with the Separation, Senior Notes Offering, Initial Public Offering and Exchange Offer— The Separation.

[8] As of December 31, 2013, there were 500,007,428 outstanding shares of common stock.